目的观察磷酸奥司他韦联合板蓝根颗粒治疗甲型H1N1流感的临床疗效。方法以我院收治的235例甲型H1N1流感患者为研究对象,随机分为实验组和对照组,其中实验组128例,应用磷酸奥司他韦联合板蓝根颗粒治疗;对照组107例,单用磷酸奥司他韦治疗。对比2组的热程、临床症状、血常规、病毒学检验、住院天数等,从而评价疗效差异。结果入院治疗第3天时,实验组在体温、咳嗽、咳痰、咽痛等临床表现恢复方面均好于对照组(P<0.05);实验组平均住院天数(5.18±3.77)d明显少于对照组平均住院天数(7.86±5.43)d(P<0.05)。结论磷酸奥司他韦联合板蓝根治疗甲型H1N1流感临床疗效明显优于单用磷酸奥司他韦。
Abstract
Objective To observe the efficacy of the treatment of influenza A (H1N1) with Oseltamivir phosphate and banlangen granules. Methods 235 in-patients who were diagnosed as having influenza A (H1N1) were divided into trial group and control group. The trial group including 128 patients was administered with oseltamivir phosphate and isatis root granules, and the control group including 107 patients was administered with oseltamivir phosphate only. The temperature period, clinical symptoms, blood routine, viral test and length of stay were compared between the 2 groups. Results After 3 days of treatment, recovery of symptoms including temperature, cough, expectoration and throat sore in the trial group was significantly better than that in control group (P<0.05). The length of stay in the trial group (5.18?3.77 d)was significantly shorter than that in the control group (7.86?5.43 d) (P<0.05). Conclusions The clinical efficacy of treatment of influenza A (H1N1) with oseltamivir phosphate and isatis root granules is better than that using oseltamivir phosphate only.
关键词
甲型H1N1流感 /
磷酸奥司他韦 /
板蓝根颗粒
Key words
influenza A (H1N1) /
oseltamivir phosphate /
isatis root granules
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
[1] 甲型H1N1流感诊疗方案(2009年第3版).中华人民共和国卫生部,http://www.moh.gov.cn/publicfiles//business/htmlfiles/H1N1/index.htm
[2] Orsted I, M lvadgaard M, Nielsen H L,et al.The first, second and third wave of pandemic influenza A(H1N1)pdm09 in North Denmark Region 2009-2011:a population-based study of hospitalizations[J].Influenza Other Respi Viruses,2013,2:306-309.
[3] Bin Cao, Xing-Wang Li, Yu Mao, et al. Clinical Features of the Initial Cases of 2009 Pandemic Influenza A (H1N1) Virus Infection in China[J]. N Engl J Med,2009,361:2507-2517.
[4] Dharan N J,Gubareva L V,Meyer J J,et al.Infection with oseltamivir-resistant influenza A(H1N1)virus in the United States[J].JAMA,2009,301(10):1034－1041.
[5] 蒋 虹,金 光,丛 喆.奥司他韦、利巴韦林和盐酸金刚乙胺对甲型H1N1流感病毒的抑制作用[J]. 中国比较医学杂志, 2011,21(2):23-25.
[6] 董 伟,王艳彩.磷酸奥司他韦预防甲型H1N1流感时引起不良反应206例报道[J].中国临床药学杂志,2011,20(2):111-113.
[7] Wang C Z, Li P, Yuan C S.Traditional Chinese herbal therapy as a treatment option for H1N1 influenza[J]. Ann Intern Med,2012,156 (2):166-167.
[8] 李雪峰,吴艳乔.药物临床试验中的随机化与盲法[J].西南军医,2011,13(2):326-327.
[9] 姜天俊,周志平,刘 捷,等.奥司他韦治疗甲型H1N1流感的疗效研究[J].Chinese General Practice,2010,13(9A):2839-2841
[10] Liu S, Yan J, Xing J, et al. Characterization of compounds and potential neuraminidase inhibitors from the n-butanol extract of Compound Indigowoad Root Granule using ultrafiltration and liquid chromatography-tandem mass spectrometry[J]. J Pharm Biomed Anal,2012,59:96-101.
[11] Tang H Y, Yan D, Zhang S F, et al. Agglutinated activity bioassay method for the determination of antivirus potency of Banlangen granula[J]. Yao Xue Xue Bao, 2010,45 (4): 479-483.
[12] 王玉涛,杨子峰,招穗珊,等.板蓝根抗甲1型流感病毒活性物质的初筛研究[J].广州中医药大学学报,2011,28(4):419-422.
[13] 徐丽华,黄 芳,陈 婷,等.板蓝根中的抗病毒活性成分[J].中国天然药物,2005,3(6):359.
[14] Lu C, Jiang Z, Fan X,et al. A metabonomic approach to the effect evaluation of treatment in patients infected with influenzaA (H1N1)[J]. Talanta, 2012, 100:51-56.
[15] Dia N,Niang M N,Diadhiou S A,et al.Spread of Influenza A(H1N1) oseltamivir-resistant viruses in Africa in 2008 confirmed by multiple introductions in Senegal[J].BMC Infect Dis, 2013, 13 (1): 106.
基金
国家“十二五”科技重大专项“新发突发传染病中西医结合临床救治研究平台”(2012ZX10004301-007)
PDF(555 KB)
